Epidermal Growth Factor Receptor as a Target for Chemotherapy
- 1 April 2005
- journal article
- review article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 5, S19-S27
- https://doi.org/10.3816/ccc.2005.s.003
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Capecitabine: the new generation of fluoropyrimidines in colorectal cancerExpert Review of Anticancer Therapy, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Why the Epidermal Growth Factor Receptor? The Rationale for Cancer TherapyThe Oncologist, 2002
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialPublished by Elsevier ,2000
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999